Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Income from Continuing Operations (2023 - 2025)

Immunome (IMNM) has disclosed Income from Continuing Operations for 3 consecutive years, with 72861000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 12.18% year-over-year to 72861000.0, compared with a TTM value of 224113000.0 through Dec 2025, up 26.71%, and an annual FY2025 reading of 224113000.0, up 26.71% over the prior year.
  • Income from Continuing Operations was 72861000.0 for Q4 2025 at Immunome, down from 60138000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 4471000.0 in Q1 2023 and bottomed at 132299000.0 in Q1 2024.
  • Average Income from Continuing Operations over 3 years is 53286916.67, with a median of 48500000.0 recorded in 2024.
  • The sharpest move saw Income from Continuing Operations crashed 2859.05% in 2024, then skyrocketed 66.26% in 2025.
  • Year by year, Income from Continuing Operations stood at 94653000.0 in 2023, then grew by 12.34% to 82970000.0 in 2024, then grew by 12.18% to 72861000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for IMNM at 72861000.0 in Q4 2025, 60138000.0 in Q3 2025, and 46478000.0 in Q2 2025.